Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
23.46 USD | -1.03% | +3.89% | -2.61% |
Apr. 12 | North American Morning Briefing : Big Banks Kick -2- | DJ |
Apr. 11 | Barclays Downgrades Exelixis to Equalweight From Overweight, Price Target is $25 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.61% | 6.99B | |
-2.05% | 104B | |
+1.75% | 97.42B | |
+0.79% | 22.2B | |
-17.81% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-16.93% | 15.06B | |
+3.67% | 13.98B | |
+33.59% | 11.66B |
- Stock Market
- Equities
- EXEL Stock
- News Exelixis, Inc.
- Exelixis : Gets FDA's Approval for Cabometyx to Treat Thyroid Cancer -- Stock Up 3% After-Hours